Kom Op Tegen Kanker Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Belgium (1924)

Organization Overview

First Clinical Trial
2017
NCT03192059
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Kom Op Tegen Kanker | Kom op tegen Kanker (Stand-up-to-Cancer), the Flemish cancer society

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Adenosarcoma (Phase 2)

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1)

Colonic Neoplasms (Phase 3)

Endometrial Neoplasms (Phase 2)

Head and Neck Neoplasms (Phase 2)

Leiomyosarcoma (Phase 2)

Lung Neoplasms (Phase 1)

Neoplasms (Phase 2)

Osteonecrosis (Phase 4)

Ovarian Neoplasms (Phase 1)

Pancreatic Neoplasms (Phase 1)

Peritoneal Neoplasms (Phase 1)

Sarcoma, Endometrial Stromal (Phase 2)

Sex Cord-Gonadal Stromal Tumors (Phase 2)

Stomach Neoplasms (Phase 1)

Uterine Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial APIs: 24